Determination of selected antiepileptic drugs in mouse brain homogenates by HPLC—DAD

• Autorzy: Wróblewski K. , Petruczynik A. , Radzik I. , Czuczwar S. J. , Waksmundzka-Hajnos M.

Identyfikatory

DOI

10.1556/1326.2017.29.2.6

• Języki publikacji: EN

Abstrakty

EN

Three independent reversed phase high-performance liquid chromatography (HPLC) procedures with diode array detection (DAD) for the analysis of carbamazepine (CBZ), topiramate (TPM), and valproic acid (VPA) have been developed in order to determine drug penetration of the blood—brain barrier. Determination of CBZ was performed on C18 column with mobile phases containing methanol (55%, v/v), acetate buffer at pH 3.5 (20%, v/v), double distilled water (25%, v/v), and 0.025 M L−1 diethylamine (DEA). The mobile phase containing acetonitrile and water (8:2, v/v) or acetonitrile and phosphate—citrate buffer at pH 2.6 (1:1), respectively, for analysis of VPA and TPM was applied. Quantification of carbamazepine was performed at 285 nm without extraction procedure before the analysis. Determination of topiramate and valproic acid was performed using precolumn derivatization with 9-fluorenylmethyl chloroformate (FMOC-Cl). FMOC-Cl is a suitable agent, which reacts with both primary and secondary amines and also with acidic groups. Topiramate was determined at 263 nm and valproic acid at 300 nm. The proposed procedures are simple, not time-consuming, and suitable for the determination of investigated compounds in mouse brain homogenates.

Słowa kluczowe

EN

carbamazepine; topiramate; valproic acid; RP-HPLC; DAD; FMOC—Cl derivatization; mouse brain homogenates

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2017
• Tom: Vol. 29, no. 2
• Strony: 219--234
• Opis fizyczny: Bibliogr. 28 poz., rys., tab.

Twórcy

autor

Wróblewski K.

• Department of Inorganic Chemistry, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland

autor

Petruczynik A.

• Department of Inorganic Chemistry, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland

autor

Radzik I.

• Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland

autor

Czuczwar S. J.

• Department of Pathophysiology, Medical University of Lublin, Jaczewskiego 8b, 20-090 Lublin, Poland

autor

Waksmundzka-Hajnos M.

• Department of Inorganic Chemistry, Medical University of Lublin, Chodźki 4a, 20-093 Lublin, Poland

Bibliografia

• [1] M.J. Martín-Vázquez, In: Dr. Farid Badria (Ed.), Psychiatric Drugs in Medical Practice, Pharmacotherapy, InTech, 2012, pp. 93–96. Available from: http: //www.intechopen.com/books/pharmacotherapy/psychiatric-drugs-in medicalpractice
• [2] R.J. Porter and B.S. Meldrum, In: B.G. Katzung (Ed.), Basic and Clinical Pharmacology, McGraw-Hill, New York, NY, 2011, p. 399
• [3] P.A. Datar, J. Pharm. Anal., 5, 213 (2015)
• [4] A. Owen, J.N. Tettey, P. Morgan, M. Pirmohamed, and B.K. Park, J. Pharm. Biomed. Anal., 26, 573 (2001)
• [5] E.C. Pinto, M.D. Dolzan, L.M. Cabral, D.W. Armstrong, and V.P. de Sousa, Biomed. Chromatogr., 29, 1461 (2015)
• [6] G. Bahrami and B. Mohammadi, J. Chromatogr. B, 850, 400 (2007)
• [7] G. Bahrami, S. Mirzaeei, and A. Kiani, J. Chromatogr. B, 813, 175 (2004)
• [8] G. Bahrami, S. Mirzaeei, B. Mohammadi, and A. Kiani, J. Chromatogr. B, 822, 322 (2005)
• [9] J.J. Luszczki, A. Wlaz, S. Karwan, M. Florek-Luszczki, and S.J. Czuczwar, Eur. J. Pharmacol., 720, 247 (2013).
• [10] D.J. Berry and P.N. Patsalos, Ther. Drug Monit., 22, 460 (2000)
• [11] A. Mohammadi, N. Rezanour, M. Ansari, and R.B. Walker, Asian J. Chem., 22, 3856 (2010)
• [12] B. Mohammadi, E. Tammari, and S. Fakhri, G. Bahrami, J. Chromatogr. B, 928, 32 (2013)
• [13] H. Amini, M. Javan, and A. Ahmadiani, J. Chromatogr. B, 830, 368 (2006)
• [14] G. Kamalinia, M.R. Rouini, and P. Ghaeli, Chromatographia, 70, 569 (2009)
• [15] M.C. Lin, H.S. Kou, C.C. Chen, S.M. Wu, and H.L. Wu, J. Chromatogr. B, 810, 169 (2004)
• [16] Y. Zhong, Z. Jiao, and Y. Yu, Biomed. Chromatogr., 2, 319 (2006)
• [17] S. Hara, M. Kamura, K. Inoue, M. Fukuzawa, N. Ono, and T. Kuroda, Biol. Pharm. Bull., 22, 975 (1999)
• [18] A. Kotani, T. Kotani, N. Ishii, H. Hakamata, and F. Kusu, J. Pharm. Biomed. Anal., 97, 47 (2014)
• [19] D.S. Jain, G. Subbaiah, M. Sanyal, and P. Shrivastav, Talanta, 72, 80 (2007)
• [20] B. Mohammadi, M.B. Majnooni, P.M. Khatabia, R. Jalili, and G. Bahrami, J. Chromatogr. B, 880, 12 (2012)
• [21] H. Cheng, Z. Liu, W. Blum, J.C. Byrd, R. Klisovic, M.R. Grever, G. Marcucci, and K.K. Chan, J. Chromatogr. B, 850, 206 (2007)
• [22] K.M. Jooa, D. Choib, Y.H. Parkd, C.G. Yia, H.J. Jeonga, J.C. Choa, and Kyung-Min. Lim, J. Chromatogr. B, 938, 35 (2013)
• [23] P. Shahdousti, A. Mohammadi, and N. Alizadeh, J. Chromatogr. B, 850, 128 (2007)
• [24] E. Gaetani, C.F. Laureri, and M. Vitto, J. Pharm. Biomed. Anal., 10, 193–197 (1992)
• [25] T.T. Pham, H.H. See, R. Morand, S. Krahenbuhl, and P.C. Hauser, J. Chromatogr. B, 907, 74 (2012)
• [26] S. Einarsson, B. Josefsson, and S. Lagerkvist, J. Chromatogr., 282, 609 (1983)
• [27] G. Bahrami and B. Mohammadi, J. Chromatogr. B, 850, 417 (2007)
• [28] R.A. Cox, In: J. Ermer, J.H. McB. Miller (Eds.), Method Validation in Pharmaceutical Analysis: A Guide to Best Practice, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 2005, p. 338.

Uwagi

PL

Opracowanie ze środków MNiSW w ramach umowy 812/P-DUN/2016 na działalność upowszechniającą naukę (zadania 2017).